Participant enrolment and retention key to clinical trial derisking
As the complexity of clinical trials continues to grow, enhancing patient centricity, improving site and contract research organisation (CRO) collaboration …
Post
-
-
How to tackle regulatory pathways and obstacles for clinical trials in UK and Ireland
The upcoming Outsourcing in Clinical Trials UK & Ireland 2026 conference, taking place on 9–10 June 2026 in London, UK, …
-
REGENXBIO to push for accelerated approval of DMD gene therapy
REGENXBIO is set to apply for US accelerated approval of its Duchenne muscular dystrophy (DMD) gene therapy after it showed …
-
Nonprofits join forces to debut marketplace for shelved CGTs
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have teamed up to launch an …
-
Tempus broadens collaboration with BMS for clinical trials
Tempus AI has expanded its strategic partnership with Bristol Myers Squibb (BMS) to optimise clinical trial designs across oncology and …
-
Biopharma industry endorses Pazdur for FDA commissioner role
With the leadership role of the US Food and Drug Administration (FDA) vacant following Marty Makary’s resignation earlier this week, …
-
Biogen forges on with Alzheimer’s therapy development despite Phase II miss
Biogen is firing up a registrational programme for its tau-focused Alzheimer’s disease therapy, diranersen, despite the drug missing its primary …
-
Three PsA trials to watch in 2026
With the European Alliance of Associations for Rheumatology’s (EULAR) 2026 meeting less than a month away, physicians, researchers and other …
-
Massive Bio and Just Worldwide to expand cancer trial access
Massive Bio has signed a strategic partnership with Just Worldwide to connect more cancer patients to clinical studies. The collaboration will …
-
Podcast: UK targets speedy clinical trial set-ups with 150-day benchmark
Faced with growing competition in the global clinical trials landscape, many countries are reforming regulatory frameworks in a bid to …
-
ECO 2026: survodutide delivers renal and metabolic benefits in DKD model
At this year’s European Congress on Obesity (ECO), during a poster session, researchers presented an analysis of the effects of …
-
UK health secretary Wes Streeting resigns
UK health secretary Wes Streeting has resigned, citing a ‘loss of faith’ in the Labour party’s leadership under Prime Minister …
-
Shionogi weighs future of FXS drug after double Phase III miss
Shionogi is mulling over the fate of its fragile X syndrome (FXS) therapy, zatolmilast, after the drug failed to meet …
-
QuartzBio secures Eir Partners investment for trial intelligence platform
QuartzBio has secured a strategic investment and majority ownership from private equity company Eir Partners to expedite its clinical trial …
-
Osel and partners launch Phase IIb FLIP-2 trial of Lactin-V
Osel, Imperial College London’s clinical trials unit and March of Dimes have launched the Phase IIb FLIP-2 trial, assessing the …
